
Opinion|Videos|April 3, 2025
Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health
Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- What interdisciplinary approaches to care can help optimize ADC therapy outcomes in patients with mBC?
- Do patients receiving ADC therapy at your practice experience adherence barriers due to social determinants of health, treatment costs, accessibility, or insurance coverage?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
FDA Approves Lerodalcibep for Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
5


















































































































































































































